Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

IPCI pending catalysts

-PODRAS patent approval
-Rexista NDA submission
-Rexista partnership with lucrative upfront payment + milestone pymt's
-Acceptance of the Rexista NDA submission by the FDA(74-day letter)
-4 additional FocalinXR strengths approved by the FDA(licensing agreement with PAR already)
-Seroquel XR commercialization May 1st, 2017(licensing agreement with Mallinckrodt already)
-FDA approval of Pristiq(licensing agreement with Mallinckrodt)
-FDA approval of Lamictal(licensing agreement with Mallinckrodt)
-FDA approval of Protonix(licensing agreement still to be secured)
-FDA approval of Effexor(licensing agreement still to be secured)
-FDA approval of Glucophage(licensing agreement still to be secured)
-FDA granting Rexista PDUFA date Q2 2017
-Ringing of opening bell on NASDAQ on the heels of 1 of the upcoming catalysts